Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hinova PharmaceuticalsSHSE:688302 -5.10%24 PS Ratio is 72.99 as of Jul. 24, 2026, which is 97% below its 10-year median of 2,526.11. GuruFocus rates SHSE:688302 with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 929 Biotechnology companies, Hinova Pharmaceuticals ranks worse than 82.35% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Hinova Pharmaceuticals's share price is ¥34.23.
Hinova Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.47. Hence, Hinova Pharmaceuticals's PS Ratio for today is 72.99.
The historical rank and industry rank for Hinova Pharmaceuticals's PS Ratio or its related term are showing as below:
SHSE:688302'
s PS Ratio Range Over the Past 10 Years
Min: 70.49 Med: 2526.11 Max: 40240
Current: 72.96
During the past 8 years, Hinova Pharmaceuticals's highest PS Ratio was 40240.00. The lowest was 70.49. And the median was 2526.11.
SHSE:688302's PS Ratio is ranked worse than 82.35% of 929
companies
in the Biotechnology industry
Industry Median: 9.13
vs SHSE:688302: 72.96
During the past 8 years, Hinova Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 125.70% per year. The lowest was -31.90% per year. And the median was 46.90% per year.
Back to Basics: PS Ratio
Hinova Pharmaceuticals (SHSE:688302) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688302 vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, Hinova Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hinova Pharmaceuticals PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hinova Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Hinova Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Hinova Pharmaceuticals's Share Price of today is ¥34.23. Hinova Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.47.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Hinova Pharmaceuticals (SHSE:688302) has a PS Ratio of 72.99 as of Jul. 24, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Hinova Pharmaceuticals and its competitors. This is 97% below median its historical median of 2,526.11. Over the past decade, Hinova Pharmaceuticals' PS Ratio has ranged from 70.49 to 40,240.00. According to the industry distribution chart, Hinova Pharmaceuticals ranks #765 out of 929 companies in the Biotechnology industry, placing it in the top 82.3%.
Is Hinova Pharmaceuticals' PS Ratio too high?
Hinova Pharmaceuticals' current PS Ratio of 72.99 is 97% below median its 10-year median of 2,526.11. Over the past 10 years, this metric has ranged from a low of 70.49 to a high of 40,240.00. The Biotechnology industry median PS Ratio is 9.13. Hinova Pharmaceuticals' value of 72.99 is 699.5% above this industry median. Based on the distribution chart, Hinova Pharmaceuticals ranks #765 out of 929 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hinova Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Hinova Pharmaceuticals' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hinova Pharmaceuticals ranks #765 out of 929 companies for PS Ratio. This places Hinova Pharmaceuticals in the lower half of its industry. The industry median PS Ratio is 9.13. Hinova Pharmaceuticals' value of 72.99 is 699.5% above this benchmark. Historically, Hinova Pharmaceuticals' own PS Ratio has ranged from 70.49 to 40,240.00 over the past decade. While the company's 10-year median is 2,526.11 vs. the industry median of 9.13, Hinova Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.13, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hinova Pharmaceuticals's current PS Ratio of 72.99 is 699.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Hinova Pharmaceuticals and its competitors. For the Biotechnology industry, the median PS Ratio is 9.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hinova Pharmaceuticals's current PS Ratio is 72.99, which is 97% below median its own 10-year median of 2,526.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hinova Pharmaceuticals stock overvalued right now?
Hinova Pharmaceuticals (SHSE:688302) has a current PS Ratio of 72.99. The current PS Ratio is 72.99, which is 97% below median its 10-year median of 2,526.11 and 699.5% above the Biotechnology industry median of 9.13. Hinova Pharmaceuticals' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Hinova Pharmaceuticals (SHSE:688302), the current PS Ratio is 72.99 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
24GF Score
Get the complete analysis for SHSE:688302
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688302 has been successfully added to your 
